BUZZ-Street View: Bioprocess woes weigh on Danaher, but bulls stay put
DHR•Broker views remain constructive
Median PT of 28 brokerages covering the stock is $225 — LSEG-compiled data.
Danaher cuts outlook but raises profit forecast
Lab equipment maker Danaher DHR.N cut its full-year core revenue growth outlook and reported weaker-than-expected revenue in its biotechnology business on Tuesday.
Co raised its annual profit forecast.
Brokers say long-term bioprocessing drivers still support the stock
- Evercore ISI ("outperform," PT: $205) says "underlying drivers are all pointing in the right direction and DHR is set up for a solid FY27"
- J.P. Morgan ("overweight," PT: $220) says, while investor frustration with uneven bioprocessing recovery is understandable, 2026 targets remain on track and underlying trends continue to improve
- Jefferies ("buy," PT: $210) expects focus to remain on whether bioproduction reset is too conservative and if next year is the right starting point, noting 2026 EPS is moving higher but multiple expansion is unlikely due to lingering visibility and portfolio questions
- Leerink Partners ("outperform," PT: $240) says current valuations don't justify stepping away, long-term bioprocess growth remains healthy, though concerns about slower-growth industry phase will likely remain
